

**DESCRIPTION**

**Source** Mouse myeloma cell line, NS0-derived  
Glu24-Lys631, with a C-terminal Ser and 10-His tag  
Accession # O00206

**N-terminal Sequence Analysis** Glu24

**Predicted Molecular Mass** 70.6 kDa

**SPECIFICATIONS**

**SDS-PAGE** 90-95 kDa, reducing conditions

**Activity** Measured by its binding ability in a functional ELISA.  
When Recombinant Human (rh) TLR4 is immobilized at 2 µg/mL (100 µL/well), the concentration of rhMD2 that produces 50% optimal binding response is found to be approximately 0.03-0.15 µg/mL.

**Endotoxin Level** <0.10 EU per 1 µg of the protein by the LAL method.

**Purity** >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

**Formulation** Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

**Reconstitution** Reconstitute at 100 µg/mL in PBS.

**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

**BACKGROUND**

TLR4 is a 100 kDa type I transmembrane glycoprotein that belongs to the mammalian Toll-Like Receptor family of pathogen pattern recognition molecules. The complex of TLR4 with MD-2 functions as a critical receptor for bacterial endotoxin/lipopolysaccharide (LPS) (1-3). Mature human TLR4 consists of a 608 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 187 aa cytoplasmic domain. TLR4 contains 21 leucine rich repeats in its ECD and one cytoplasmic Toll/IL-1 receptor (TIR) domain (4). The ECD of human TLR4 shares approximately 25% aa sequence identity with other human TLRs and 60%-74% aa sequence identity with bovine, equine, feline, mouse, rat, and porcine TLR4. On monocytes, macrophages, dendritic cells, and B cells, MD-2 expression is required for cell surface localization of TLR4 and for optimal LPS-induced TLR4 signaling (5-8). MD-2 also forms soluble disulfide-linked homo-oligomers which can interact with TLR4 (6). Through a domain separate from its TLR4-binding domain, MD-2 extracts LPS from circulating CD14-LPS complexes and carries the LPS into a ternary complex with TLR4 (9-11). The interaction of MD-2/LPS with TLR4 induces receptor oligomerization and the triggering of an inflammatory response (2, 12). Increased levels of plasma MD-2 in septic shock patients sensitizes MD-2 non-expressing epithelial cells to LPS and promotes widespread tissue inflammation (13).

**References:**

1. Miyake, K. (2004) *Semin. Immunol.* **16**:11.
2. Verstrepen, L. *et al.* (2008) *Cell. Mol. Life Sci.* **65**:2964.
3. Erridge, C. (2010) *J. Leukoc. Biol.* **87**:989.
4. Medzhitov, R. *et al.* (1997) *Nature* **388**:394.
5. Shimazu, R. *et al.* (1999) *J. Exp. Med.* **189**:1777.
6. Visintin, A. *et al.* (2001) *Proc. Natl. Acad. Sci.* **98**:12156.
7. Akashi, S. *et al.* (2000) *J. Immunol.* **164**:3471.
8. Nagai, Y. *et al.* (2002) *Nat. Immunol.* **3**:667.
9. Re, F. and J.L. Strominger (2003) *J. Immunol.* **171**:5272.
10. Kennedy, M.N. *et al.* (2004) *J. Biol. Chem.* **279**:34698.
11. Gioannini, T.L. *et al.* (2004) *Proc. Natl. Acad. Sci.* **101**:4186.
12. Saitoh, S. *et al.* (2004) *J. Endotoxin Res.* **10**:257.
13. Pugin, J. *et al.* (2004) *Blood* **104**:4071.